Long Shortz with Race Oncology: Study proves effective for Acute myeloid leukaemia drug

Stockhead’s Sarah Hughan sits down with Race Oncology’s (ASX:RAC) CEO Dr Daniel Tillett to get the short end of the long story on the company’s latest news.

The biopharmaceutical company has successfully concluded a Phase 2 trial of its Bisantrene drug for patients with AML – acute myeloid leukaemia.

The study had some excellent results with patients who had exhausted other standard chemotherapeutics.

Tune in to hear Race Oncology’s Dr Daniel Tillett on the trial’s positive outcomes, the next cancer study, and more.

This video was developed in collaboration with Race Oncology, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.